Oxygen
Biotherapeutics OXBT today announced the Company has received approximately $6
million through the exercise of 2,294,874 warrants between November 4,
2013 and November 6, 2013. These warrants were issued by the Company in
connection with its July 2013 Series C 8% Convertible Preferred Stock
financing. Following these warrant exercises, 9,112,307 shares of the
Company's common stock were issued and outstanding as of November 7,
2013.
“The exercise of these warrants increases our current cash on hand to
approximately $8.4 million. Upon closing of the previously announced
Phyxius Pharma transaction, we expect to be in a position to commence
the Phase 3
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in